A triptan called zolmitriptan is used to treat migraine attacks with or without aura as well as cluster headaches. It is marketed under the brand names Zomig and other names. It is a selective agonist of the 1B and 1D subtypes of serotonin receptors.
Zolmitriptan frequently reduces migraine-related symptoms such nausea, vomiting, sensitivity to light, and sensitivity to sound. An ordinary painkiller is not what zolmitriptan is. Except for migraine headaches, it shouldn’t be used to ease any other type of discomfort.
Zolmitriptan side effects could perhaps become more likely if taken in excess. Significant efficacy is visible within an hour after dosage in people who respond.
The Global Zolmitriptan Market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
Today, Impax Laboratories announced that its generics division, Global Pharmaceuticals, had started shipping authorised generic Zomig® (zolmitriptan) tablets and orally disintegrating tablets, 2.5 mg and 5 mg, in the United States as part of a Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited (AstraZeneca).
Adults who suffer from migraine headaches can use Zomig to treat them. Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company with a technology foundation.
In addition to creating branded products for conditions of the central nervous system, Impax uses its formulation expertise and drug delivery technology to create controlled-release and specialty generics.
Global Pharmaceuticals, a branch of Impax, handles the marketing of its generic drugs, while Impax Pharmaceuticals handles the marketing of its branded products.
Impax also pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments, and develops marketing partnerships when it is strategically appropriate to do so in order to fully leverage its technology platform.
These statements are forward-looking in nature and indicate management’s thoughts and expectations to the degree that they contain information that is not historical in this news release.
These predictions are based on current estimates and contain a variety of known and unknowable risks and uncertainties that could cause the Company’s actual results, performance, or achievements to materially differ from those projected in such forward-looking statements.
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.